Key facts

Invented name
  • Revlimid
  • Revlimid
Active Substance
lenalidomide
Therapeutic area
Oncology
Decision number
P/102/2008
PIP number
EMEA-000371-PIP01-08
Pharmaceutical form(s)
Capsule (hard)
Condition(s) / indication(s)
Myelodysplastic Syndrome
Route(s) of administration
Oral use
Contact for public enquiries

Celgene Europe Limited

E-mail: medinfo.intl@celgene.com
Country: Switzerland
Phone: +41 327298500
Fax: +41 327298508

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/102/2008: European Medicines Agency decision of 6 November 2008 on the application for product specific waiver for lenalidomide (Revlimid) (EMEA-000371-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the E...

How useful do you find this page?